Commercial Strategy and Market Access Sales Sheet
Fullscreen Mode
Traditional CROs fragment device development with costly hand-offs and learning curves. Veranex unites the essential disciplines for medical device & diagnostic development under one roof from sketch to evidence-generation to market launch.
All connected. All aligned. All accelerating your path to market—delivering breakthrough devices and diagnostics that improve patient lives sooner.
Breakthrough innovation requires more than great solutions; it demands deep expertise and insight. Veranex packages outcome-driven solutions with 25+ years of specialized knowledge across major medtech categories, delivering integrated capabilities that solve your most pressing challenges faster and with greater certainty.
Purpose-built solutions. Proven results. User & Patient-centered innovation.
Whether you're transforming patient care or disrupting entire therapeutic categories, innovation requires more than great science, it demands velocity. Veranex was founded to bridge the gap between visionary concepts and market reality, combining proven expertise with agile execution to accelerate the innovations that matter most.
We are the Innovation CRO.
Legacy of excellence. Proven execution. Patient impact accelerated.
Fullscreen Mode
3 min read
Background A leading global medical device manufacturer faced a pricing strategy challenge and partnered with Veranex (formerly Boston Healthcare...
By developing a cost-effectiveness model and associated manuscript for home non-invasive ventilation in patients with persistent hypercapnia after an...
By leading the manuscript development, Veranex supported Philips Healthcare in publishing real-world evidence data supporting the use of Mobile...
Veranex Director Lauren Fusfeld uses a case study to show how conjoint analysis can demonstrate to payers and health care providers the clinical...
By conducting a clinical utility study for Proteomics International’s PromarkerD (a blood-based test that predicts the risk of kidney disease/decline...
Veranex’s Commercial Strategy and Market Access team members, Manasi Datar, PhD, Li-Chen Pan, MPH, and Thomas F. Goss, PharmD, along with members...
225,000 vitrectomy surgeries are performed annually in the U.S. A time-driven cost analysis conducted at a US academic hospital found the average...
This study compares the health and economic outcomes of using mobile cardiac outpatient telemetry (MCOT) and implantable loop recorders (ILRs) for...
By developing a U.S. payer budget impact model and associated manuscript for Thermo Fisher’s Molecular Microscope® MMDx®-Kidney (a microarray with...